A Review of the First Year of Medicare Coverage of Erythropoietin

Recombinant human erythropoietin (rHuEPO) is a new drug for treating anemia associated with end stage renal disease (ESRD). In a study of rHuEPO diffusion, costs, and effectiveness, we analyze ESRD program data and all claims submitted to Medicare for reimbursement of rHuEPO administered to ESRD dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Robert I., Powe, Neil R., Greer, Joel, de Lissovoy, Gregory, Anderson, Gerard F., Whelton, Paul K., Watson, Alan J., Eggers, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CENTERS for MEDICARE & MEDICAID SERVICES 1994
Materias:
Prescription Drugs: Payment and Policy Issues
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193448/
https://www.ncbi.nlm.nih.gov/pubmed/10137799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193448/
https://www.ncbi.nlm.nih.gov/pubmed/10137799

Ejemplares similares